George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. The private U.S. company disclosed the equity financing in a Securities and Exchange Commission document ...

The CEO of a biotechnology company is suing rideshare giant Uber, claiming he was attacked by one of its drivers and left with a brain injury. Bryan Kobel, CEO of TC BioPharm, claims the attack ...

Microsoft has backed out of building data centers, Intel's factory opening has been delayed to 2030, but one tech industry is going strong in central Ohio: Biotechnology. The now multibillion dollar ...

The industry group MassBio has released its annual temperature check on the biotech industry in Massachusetts, and the results are grim. Both public and private funding have plummeted as federal ...

A biotech CEO is taking Uber to court after an illegal immigrant driver was caught on camera violently assaulting him in downtown Charleston, South Carolina, sending his dog crashing to the pavement.

In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy Under $10. The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC’s “Squawk Box” on July 25 to ...

The first microchip was invented in Texas in the 1950s, but many of today’s most advanced chips are made in Taiwan and South Korea. Last week, the U.S. government purchased a 10% stake in the ...

Steven Cohen bought $17.2 million of Invivyd on Tuesday. Point72 liftedDesign stake by 62.8% on Wednesday. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Steven Cohen isn't ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. Neurizon, an Australian biotech focusing on neurodegenerative diseases, will now have to wait until ...